

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Review Proposal Project

## NICE Technology Appraisal No.464; Bisphosphonates for treating osteoporosis

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company(ies)</u></p> <ul style="list-style-type: none"> <li>• AAH (alendronate, ibandronate, risedronate)</li> <li>• Accord Healthcare (alendronate, ibandronate, risedronate)</li> <li>• Actavis UK (alendronate, ibandronate)</li> <li>• Almus Pharmaceuticals (alendronate, risedronate)</li> <li>• Amneal Pharma Europe (zoledronate)</li> <li>• Atnas Pharma (ibandronate)</li> <li>• Aspire (ibandronate, risedronate)</li> <li>• Aurobindo (alendronate)</li> <li>• Consilient Health (ibandronate)</li> <li>• Creo Pharma (alendronate, risedronate)</li> <li>• DE Pharmaceuticals (alendronate, ibandronate, risedronate)</li> <li>• Dr Reddy's Laboratories (zoledronate)</li> <li>• Genesis Pharmaceuticals (ibandronate)</li> <li>• Hospira UK (zoledronate)</li> <li>• Internis (alendronate)</li> <li>• Intrapharm Laboratories (zoledronate)</li> <li>• Mawdsely-Brooks &amp; Company (alendronate, ibandronate, risedronate)</li> <li>• Merck Sharp &amp; Dohme (alendronate)</li> <li>• Mylan UK (alendronate, ibandronate, risedronate)</li> <li>• Novartis Pharmaceuticals (zoledronate)</li> <li>• Ranbaxy (ibandronate, zoledronate)</li> <li>• Roche (ibandronate)</li> <li>• Rosemont (alendronate)</li> <li>• Sandoz (risedronate)</li> <li>• Seacross Pharmaceuticals (zoledronate)</li> <li>• Sigma pharmaceuticals (ibandronate,</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator company(ies)</u></p> <p>None</p> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Bone Research Society</li> <li>• Chronic Pain Policy Coalition</li> <li>• Cochrane Musculoskeletal Group</li> <li>• Genomics England</li> <li>• Institute for Ageing and Health</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Orthopaedic Research UK</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<p>risedronate)</p> <ul style="list-style-type: none"> <li>• Somex (alendronate)</li> <li>• Sovereign Medical (risedronate)</li> <li>• Teva UK (alendronate, ibandronate, risedronate)</li> <li>• Waymade Healthcare (alendronate, ibandronate, risedronate)</li> <li>• Warner Chilcott UK (risedronate)</li> <li>• Wockhardt Healthcare (alendronate)</li> <li>• Zentiva (alendronate)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Arthritis and Musculoskeletal Alliance</li> <li>• Back Care</li> <li>• Disability Rights UK</li> <li>• Leonard Cheshire Disability</li> <li>• Muslim Council of Britain</li> <li>• National Osteoporosis Society</li> <li>• Pain Concern</li> <li>• Pain Relief Foundation</li> <li>• Pain UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Women's Health Concern</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Geriatrics Society</li> <li>• British Institute of Musculoskeletal Medicine</li> <li>• British Menopause Society</li> <li>• British Orthopaedic Association</li> <li>• British Society of Rehabilitation Medicine</li> <li>• Physiotherapy Pain Association</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Society of Medicine</li> <li>• Society for Endocrinology</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p>	

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS Ashford CCG</li> <li>• NHS England</li> <li>• NHS Isle of Wight CCG</li> <li>• Welsh Government</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

**Definitions:**

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal.

These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.